Efficacy News and Research

RSS

Study: Drugs that block NPC1 protein could be used to treat Ebola virus disease

A new study has demonstrated that a protein called Niemann-Pick C1 (NPC1) is critical for the Ebola virus to infect a host. The study, published in the May/June issue of mBio, the online open-access journal of the American Society for Microbiology, suggests that drugs that block NPC1 could be used to treat this deadly disease.

27 May 2015

Commuting stress factors can lead to burnout

Commuting length, distance, and means are stress factors that can lead to burnout, says Annie Barreck of the University of Montreal's School of Industrial Relations. "A correlation exists between commuting stress factors and the likelihood of suffering from burnout.

26 May 2015

CVRx announces presentation of positive data from Barostim Therapy for Heart Failure clinical trial at HRS 2015

CVRx, Inc., a private medical device company, announced that positive results from the 'Barostim Therapy for Heart Failure' randomized, controlled clinical trial were presented at the 2015 annual Scientific Sessions of the Heart Rhythm Society (HRS) in a Late-Breaking Clinical Trial Session. Results were presented by Dr. Michael Zile from the Medical University of South Carolina.

26 May 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

Today, Rhodes Pharmaceuticals L.P. announced that Aptensio XR, a once-daily central nervous system stimulant indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will be available to patients beginning Summer 2015.

22 May 2015

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension.

21 May 2015

Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

21 May 2015

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

Regeneron Pharmaceuticals, Inc. and Sanofi announced today that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.

21 May 2015

Discovery Lab enrolls first patient in phase 2a clinical trial of AEROSURF

Discovery Laboratories, Inc., a specialty biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today reported that the first patient has been enrolled in the next phase of its phase 2a clinical evaluation of AEROSURF, which is designed to evaluate the safety and tolerability of higher and repeat doses of aerosolized KL4 surfactant administered to premature infants 29 to 34 weeks gestational age (GA) who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS), compared to infants receiving nCPAP alone.

20 May 2015

New data shows safety and efficacy of biosimilar infliximab treatment in IBD patients

Clinical experience of biosimilar infliximab in 78 inflammatory bowel disease (IBD) patients presented at Digestive Diseases Week (DDW) 2015 in Washington D.C. showed that the treatment is comparable to the reference medicinal product (RMP) in terms of efficacy and safety.

20 May 2015

Johns Hopkins researchers identify new therapy to treat lung cancer

A multidisciplinary team led by Johns Hopkins researcher Venu Raman, Ph.D., with notable contributions from Guus Bol, Farhad Vesuna and Phuoc Tran of Johns Hopkins, has identified a new therapy for lung cancer, the most common cancer worldwide. The therapy has been in development for six years and involves a first-in-class molecule designed by the team.

20 May 2015

Corus CAD test can help clinicians rule-out low-risk patients from additional cardiac testing

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today results from a multi-center, community-based patient registry, the PRESET Registry, evaluating the use of the Corus CAD test in patients with symptoms suggestive of obstructive coronary artery disease (CAD) in the primary care setting.

20 May 2015

Study shows trophon EPR effective in inactivating high-risk, cancer-causing HPV

A new study presented at the Society for Healthcare Epidemiology of America has demonstrated that the trophon EPR is the only high level disinfection system proven to kill natural, infectious, high-risk human papilloma virus (HPV) under normal use conditions.

20 May 2015

Study shows trophon EPR effective in inactivating high-risk, cancer-causing HPV

20 May 2015

Promising preliminary results for AKB-9778 in diabetic macular oedema

AKB-9778, a small molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase, has a good safety and efficacy profile in patients with diabetic macular oedema, suggests a preliminary dose-escalation study.

19 May 2015

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.

19 May 2015

DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).

19 May 2015

ORIG3N, LabCorp form strategic partnership

ORIG3N, Inc., a pioneer in regenerative medicine and provider of induced pluripotent stem cell (iPSC) storage, called LifeCapsule, today announced a strategic collaboration with Laboratory Corporation of America Holdings.

19 May 2015

Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

Shionogi Inc. today announced data from a Phase IIb study that showed 0.2 mg and 0.4 mg of naldemedine demonstrated statistically significant efficacy in treating opioid-induced constipation (OIC) in patients with chronic non-cancer pain.

19 May 2015

vTv Therapeutics enrolls first patients in azeliragon Phase 3 trial for treatment of mild Alzheimer's disease

vTv Therapeutics LLC today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's Phase 3 placebo controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer's disease.

19 May 2015

Cryoport net revenues increase 44% to $1.2 million in fourth quarter 2015

Cryoport, Inc. today announced financial results for the three and twelve-month periods ended March 31, 2015.

19 May 2015

Efficacy News and Research

Study: Drugs that block NPC1 protein could be used to treat Ebola virus disease

Commuting stress factors can lead to burnout

CVRx announces presentation of positive data from Barostim Therapy for Heart Failure clinical trial at HRS 2015

Aptensio XR once-daily treatment for ADHD to be available in Summer 2015

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

SARIL-RA-TARGET trial: Sarilumab meets co-primary efficacy endpoints in RA patients

Discovery Lab enrolls first patient in phase 2a clinical trial of AEROSURF

New data shows safety and efficacy of biosimilar infliximab treatment in IBD patients

Johns Hopkins researchers identify new therapy to treat lung cancer

Corus CAD test can help clinicians rule-out low-risk patients from additional cardiac testing

Study shows trophon EPR effective in inactivating high-risk, cancer-causing HPV

Study shows trophon EPR effective in inactivating high-risk, cancer-causing HPV

Promising preliminary results for AKB-9778 in diabetic macular oedema

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

ORIG3N, LabCorp form strategic partnership

Naldemedine shows promise in treating OIC in patients with chronic non-cancer pain.

vTv Therapeutics enrolls first patients in azeliragon Phase 3 trial for treatment of mild Alzheimer's disease

Cryoport net revenues increase 44% to $1.2 million in fourth quarter 2015

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News